

## Possible gluten sensitivity in multiple system atrophy

M.T. Pellecchia, MD; G. Ambrosio, MD; E. Salvatore, MD;  
C. Vitale, MD; G. De Michele, MD; and P. Barone, MD

Celiac disease (CD) is an intestinal syndrome characterized by immunologic intolerance to dietary gluten leading to mucosal atrophy and malabsorption. Neurologic complications occur in 8 to 10% of patients with the disease.<sup>1</sup> Neurologic impairment can be the only manifestation of gluten sensitivity. Gluten sensitivity is indicated by increased levels of circulating antibodies to gliadin.<sup>2</sup> Most patients with gluten sensitivity carry a particular HLA variant, DQ2, or in a few cases HLA DQ8.<sup>3</sup> A high frequency of gluten sensitivity in the absence of signs and symptoms of classic CD has been found in patients with certain neurologic syndromes of unknown etiology, including cerebellar ataxia.<sup>4</sup>

Multiple system atrophy (MSA) is a sporadic, adult-onset neurodegenerative disease of unknown etiology. We studied the occurrence of gluten sensitivity in a population of MSA patients versus patients affected by idiopathic PD.

**Patients and methods.** We studied 16 patients with MSA (8 men, 8 women) with a mean age of 62.5 years (SD 8 years); mean disease duration was 5.4 years (SD 2.3 years) and 16 patients with PD (10 men, 6 women) with a mean age of 61.9 years (SD 7.2 years); mean disease duration was 5.8 years (SD 4 years) consecutively seen in our movement disorder clinic. A diagnosis of probable MSA was made according to Quinn's criteria. Twelve of 16 patients with MSA had predominant parkinsonism (MSA-P), while four of them had predominant cerebellar features (MSA-C). PD patients fulfilled UK PD Society Brain Bank diagnostic criteria.

Gastrointestinal complaints except constipation were investigated in all patients. Indicators of malabsorption, including hemoglobin, folate, iron, and calcium, were screened in both groups. IgG and IgA antigliadin antibodies (AGA) were detected by ELISA (Alfa-Gliatest, Eurospital, Trieste, Italy) in duplicate 5- $\mu$ L serum samples. Antiendomysium antibodies (EMA IgA) were measured by indirect immunofluorescence.

Subjects with positive AGA or EMA test results underwent HLA typing and were offered endoscopic biopsy of the duodenal mucosa to evaluate for the presence of gluten-sensitive enteropathy. Histologic diagnosis criteria were villous atrophy, elongated

crypts, and increase of intraepithelial lymphocytes in the lamina propria.<sup>2</sup> All subjects gave informed consent.

**Results.** No difference was observed in age and disease duration between groups, but disease severity was higher in MSA-P (median Hoehn & Yahr stage 4) than in PD patients (median Hoehn & Yahr stage 3; table).

Three of 16 patients with MSA (18.7%) had raised IgA AGAs (>3 U/mL; normal values <1 U/mL). HLA typing of IgA AGA-positive patients revealed in all cases the presence of an HLA-DQ2 phenotype; HLA typing was performed in 10 of 29 of the AGA-negative patients, none of whom had the DQ2 or DQ8 variant. Two patients with raised AGAs underwent endoscopic biopsy that showed nonspecific duodenitis with increased intraepithelial lymphocytes but no villous atrophy in either patient. There was no difference in neurologic findings between the IgA AGA-positive patients and the other IgA AGA-negative, MSA-C, and MSA-P patients. Mild cortical and subcortical atrophy on MRI was present in two IgA AGA-positive patients (Patients 17 and 32). In Patient 20, who refused duodenal biopsy, brain MRI showed moderate cerebellar atrophy and small hyperintense lesions on T2 in the frontal white matter, and a nerve conduction study revealed mild axonal sensorimotor neuropathy. No PD patient was AGA or EMA positive.

We found no difference in gastrointestinal complaints between antigliadin-positive and -negative patients. None of the patients enrolled in the study reported diarrhea, weight loss, or flatulence, which are typical features of classic CD.

**Discussion.** The prevalence of gluten sensitivity in Italy ranges from 1 in 184 to 1 in 305 based on population studies.<sup>5,6</sup> Three of our 16 patients with MSA had positive IgA AGA vs none of 16 PD patients. This frequency (18.7%) is higher than that observed in large population studies and is similar to that we found in patients with idiopathic ataxia,<sup>7</sup> suggesting a possible role for gluten sensitivity in the pathogenesis of some cases of MSA. Alternatively, gluten sensitivity might be responsible for some cases phenotypically resembling MSA. To determine the prevalence of gluten sensitivity in MSA, our findings need to be confirmed in a larger cohort of patients with a healthy control comparison group.

*From the Department of Neurological Sciences, University "Federico II", Naples, Italy.*

*Received November 1, 2001. Accepted in final form June 20, 2002.*

**Table** Demographic and clinical features of patients with PD and MSA

Patient no./sex/age, y	Disease			Signs of possible malabsorption	AGA/EMA
	Diagnosis	duration, y	Hoehn & Yahr stage		
1/F/55	PD	4	2	No	N
2/M/70	PD	1	1.5	No	N
3/M/54	PD	3	1.5	No	N
4/M/53	PD	8	2.5	No	N
5/F/72	PD	10	3	Hypocalcemia	N
6/M/64	PD	1	1.5	No	N
7/F/65	PD	10	3	No	N
8/M/58	PD	1	1.5	No	N
9/F/61	PD	7	3	No	N
10/F/45	PD	8	3	No	N
11/M/63	PD	5	3	No	N
12/M/65	PD	8	3	No	N
13/M/65	PD	15	3	Iron deficiency	N
14/F/67	PD	1	2	No	N
15/M/64	PD	7	3	No	N
16/F/70	PD	5	2.5	Folate deficiency	N
17/M/69	MSA-P	4	5	Mild hypocalcemia	IgA AGA +
18/F/53	MSA-C	10	—	Iron deficiency, hypocalcemia	N
19/M/73	MSA-C	4	—	No	N
20/M/71	MSA-C	5	—	No	IgA AGA +
21/M/67	MSA-P	5	4	No	N
22/F/60	MSA-P	6	5	No	N
23/F/48	MSA-C	7	—	No	N
24/F/65	MSA-P	7	5	No	N
25/F/68	MSA-P	6	3	No	N
26/M/65	MSA-P	5	4	No	N
27/F/54	MSA-P	3	4	No	N

**Table** Continued

Patient no./sex/age, y	Disease			Signs of possible malabsorption	AGA/EMA
	Diagnosis	duration, y	Hoehn & Yahr stage		
28/M/75	MSA-P	6	2.5	No	N
29/M/52	MSA-P	2	2.5	Iron deficiency	N
30/F/59	MSA-P	10	4	No	N
31/F/64	MSA-P	5	4	No	N
32/M/57	MSA-P	2	2	Hypocholesterolemia	IgAAGA+

AGA = anti gliadin antibodies; EMA = anti endomysium antibodies; MSA = multiple system atrophy; N = normal; MSA-P = MSA with predominant parkinsonism; MSA-C = MSA with predominant cerebellar features.

Address correspondence and reprint requests to Dr. Paolo Barone, *Clinica Neurologica, Ed. 17, Department of Neurological Sciences, Via S. Pansini 5, 80131 Napoli, Italy; e-mail: barone@unina.it*

Copyright © 2002 by AAN Enterprises, Inc.

## References

1. Finelli PF, McEntee WJ, Ambler M, et al. Adult celiac disease presenting as cerebellar syndrome. *Neurology* 1980;30:245–249.
2. Marsh MN. Gluten, major histocompatibility complex and the small intestine: a molecular and immunologic approach to the spectrum of gluten sensitivity (celiac sprue). *Gastroenterology* 1992;102:330–354.
3. Kaknoff MF. Genetic basis of coeliac disease—role of HLA genes. In: Marsh MN, ed. *Coeliac disease*. Boston: Blackwell, 1992:215–238.
4. Hadjivassiliou M, Gibson A, Davies-Jones GAB, et al. Does cryptic gluten sensitivity play a part in neurological illness? *Lancet* 1996;347:369–371.
5. Catassi C, Ratsch M, Fabiani E, et al. Coeliac disease in the year 2000: exploring the iceberg. *Lancet* 1994;343:200–203.
6. Catassi C, Fabiani E, Ratsch IM, et al. The celiac iceberg in Italy: a multicentre anti gliadin antibodies screening for celiac disease school-age subjects. *Acta Paediatr Suppl* 1996;412:29–35.
7. Pellicchia MT, Scala R, Filla A, et al. Idiopathic cerebellar ataxia associated with celiac disease: lack of distinctive neurological features. *J Neurol Neurosurg Psychiatry* 1999;66:32–35.